| First Author | Zheng D | Year | 2024 |
| Journal | Life Sci Alliance | Volume | 7 |
| Issue | 7 | PubMed ID | 38724194 |
| Mgi Jnum | J:347978 | Mgi Id | MGI:7639565 |
| Doi | 10.26508/lsa.202402602 | Citation | Zheng D, et al. (2024) Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo. Life Sci Alliance 7(7) |
| abstractText | NUT carcinoma (NC) is an aggressive cancer with no effective treatment. About 70% of NUT carcinoma is associated with chromosome translocation events that lead to the formation of a BRD4::NUTM1 fusion gene. Because the BRD4::NUTM1 gene is unequivocally cytotoxic when ectopically expressed in cell lines, questions remain on whether the fusion gene can initiate NC. Here, we report the first genetically engineered mouse model for NUT carcinoma that recapitulates the human t(15;19) chromosome translocation in mice. We demonstrated that the mouse t(2;17) syntenic chromosome translocation, forming the Brd4::Nutm1 fusion gene, could induce aggressive carcinomas in mice. The tumors present histopathological and molecular features similar to human NC, with enrichment of undifferentiated cells. Similar to the reports of human NC incidence, Brd4::Nutm1 can induce NC from a broad range of tissues with a strong phenotypical variability. The consistent induction of poorly differentiated carcinoma demonstrated a strong reprogramming activity of BRD4::NUTM1. The new mouse model provided a critical preclinical model for NC that will lead to better understanding and therapy development for NC. |
